Physician profile
Ashley A Smith
NPI 1053579979
$8,345.15
in general payments reported to CMS, 2019-2025
32 companies · $819 in 2025
The $819 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,211 · 2020: $645 · 2021: $1,209 · 2022: $1,477 · 2023: $833 · 2024: $1,151 · 2025: $819.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,788 · Education: $15.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,787.67 |
| Education | $15.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $1,556.32 | 2019-2023 | Xeomin |
| Abbvie INC. | $1,052.09 | 2019-2025 | Botox, Skyrizi |
| Allergan, INC. | $676.37 | 2019-2022 | |
| Lilly USA, LLC | $454.60 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Revance Therapeutics, INC. | $403.06 | 2024-2025 | Daxxify |
| Pfizer INC. | $401.61 | 2019-2025 | |
| Leo Pharma INC. | $354.95 | 2019-2025 | Adbry, Anzupgo |
| Galderma Laboratories, L.P. | $354.79 | 2019-2025 | Epsolay, Aklief, Nemluvio |
| Janssen Biotech, INC. | $346.09 | 2019-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $336.56 | 2019-2025 | |
| Strata Skin Sciences, INC. | $322.37 | 2019-2023 | Xtrac |
| Amgen INC. | $313.46 | 2022-2024 | Otezla |
| Sun Pharmaceutical Industries INC. | $296.52 | 2019-2024 | Absorica Ld, Winlevi |
| Haemonetics Corporation | $222.94 | 2019-2024 | Teg6s Hemostasis System |
| Regeneron Healthcare Solutions, INC. | $218.17 | 2021-2025 | Dupixent, Libtayo |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $213.89 | 2022-2025 | Opzelura |
| Ucb, INC. | $140.26 | 2021-2024 | Bimzelx, Cimzia |
| Dermira, INC. | $114.28 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $107.95 | 2019-2020 | |
| Organon LLC | $74.05 | 2025 | |
| Sientra, INC. | $72.91 | 2020 | |
| Genzyme Corporation | $71.15 | 2019-2020 | |
| Dusa Pharmaceuticals, INC. | $48.86 | 2019 | |
| Genentech USA, INC. | $31.78 | 2023 | Xolair |
| Journey Medical Corporation | $25.05 | 2019 | |
| Mayne Pharma Commercial LLC | $24.69 | 2019 | |
| Krystal Biotech INC | $22.14 | 2023 | Vyjuvek |
| Biofrontera INC. | $21.69 | 2019 | |
| Arcutis Biotherapeutics, INC. | $18.41 | 2025 | Zoryve |
| Taro Pharmaceuticals USA, INC. | $18.17 | 2019 | |
| Mission Pharmacal Company | $15.97 | 2019 | |
| Dermavant Sciences, INC. | $14.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.